新型抗生素在重症监护病房革兰阴性菌感染中的地位:共识会议报告
SRLF于2022年12月组织共识会议,由无利益冲突的委员会确定5种新型β-内酰胺类/β-内酰胺酶抑制剂(头孢洛扎-他唑巴坦、头孢他啶-阿维巴坦、亚胺培南-西司他丁-雷利巴坦、美罗培南-伐硼巴坦、头孢地尔),基于PICO模型提出6个问题并检索文献,采用GRADE方法评估证据质量,由7位专家公开作答,10位无利益冲突的重症医师组成的评审团闭门48小时撰写推荐。因常缺乏采用临床重要判断标准的强力研究,推荐常以专家意见形式给出,最终形成17条声明,回答6个问题:经验性使用、多种敏感药物时的优先选择、联合方案、碳青霉烯节约策略、危重患者给药方式优化、肾功能不全/肝细胞功能不全/肥胖的剂量调整。这些推荐旨在优化ICU患者中新型β-内酰胺类/β-内酰胺酶抑制剂的使用。
要点
- SRLF 2022年12月共识会议针对ICU革兰阴性菌感染中新型β-内酰胺类/β-内酰胺酶抑制剂的使用,最终形成17条声明回答6个问题。
- 涉及的药物包括头孢洛扎-他唑巴坦、头孢他啶-阿维巴坦、亚胺培南-西司他丁-雷利巴坦、美罗培南-伐硼巴坦和头孢地尔。
- 因常缺乏采用临床重要判断标准的强力研究,推荐常以专家意见形式给出。
- 6个问题涵盖经验性使用、药物优先选择、联合方案、碳青霉烯节约策略、给药方式优化及特殊人群剂量调整。
适用人群与场景
- ICU患者中革兰阴性菌感染(包括碳青霉烯酶产生肠杆菌和非发酵碳青霉烯耐药菌)
处置流程与药物剂量
- 经验性使用新型β-内酰胺类/β-内酰胺酶抑制剂需考虑其在ICU中的地位(问题1)。
- 当感染对多种新型分子敏感时,需基于药代动力学、药效学、生态学或医学经济学元素进行优先选择(问题2)。
- 需明确这些分子可能的联合方案及适用背景(问题3)。
- 应评估是否将这些新分子纳入碳青霉烯节约策略(问题4)。
- 需利用药代动力学和药效学数据优化危重患者的给药方式(问题5)。
- 肾功能不全、肝细胞功能不全或肥胖患者需进行剂量调整(问题6)。
研究设计与关键结果
- SRLF于2022年12月组织共识会议,由无利益冲突的委员会确定5种新型β-内酰胺类/β-内酰胺酶抑制剂,基于PICO模型提出6个问题并检索文献,采用GRADE方法评估证据质量,7位专家公开作答,10位无利益冲突的重症医师组成的评审团闭门48小时撰写推荐,最终形成17条声明。
证据类型、等级与局限
- 证据类型:共识会议(指南);采用GRADE方法评估证据质量;因常缺乏采用临床重要判断标准的强力研究,推荐常以专家意见形式给出。
- 局限:原文未报告局限性
对床旁实践的改变
- 这些推荐旨在优化ICU患者中新型β-内酰胺类/β-内酰胺酶抑制剂的使用(作者结论)。
指南或共识出处
- SRLF共识会议,2022年12月
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: New beta-lactams, associated or not with beta-lactamase inhibitors (NBs/BIs), can respond to the spread of carbapenemase-producing enterobacteriales and nonfermenting carbapenem-resistant bacteria. The risk of emergence of resistance to these NBs/BIs makes guidelines necessary. The SRLF organized a consensus conference in December 2022.
METHODS: An ad hoc committee without any conflict of interest (CoI) with the subject identified the molecules (ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam and cefiderocol); defined 6 generic questions; drew up a list of subquestions according to the population, intervention, comparison and outcomes (PICO) model; and reviewed the literature using predefined keywords. The quality of the data was assessed using the GRADE methodology. Seven experts in the field proposed their own answers to the questions in a public session and answered questions from the jury (a panel of 10 critical-care physicians without any CoI) and the public. The jury then met alone for 48 h to write its recommendations. Due to the frequent lack of powerful studies that have used clinically important criteria of judgment, the recommendations were formulated as expert opinions as often as necessary.
RESULTS: The jury provided 17 statements answering 6 questions: (1) Is there a place in the ICU for the probabilistic use of new NBs/IBs active against Gram-negative bacteria? (2) In the context of documented infections with sensitivity to several of these molecules, are there pharmacokinetic, pharmacodynamic, ecological or medico-economic elements for prioritization? (3) What are the possible combinations with these molecules and in what context? (4) Should we integrate these new molecules into a carbapenem-sparing strategy? (5) What pharmacokinetic and pharmacodynamic data are available to optimize their mode of administration in critically ill patients? (6) What are the dosage adaptations in cases of renal insufficiency, hepatocellular insufficiency or obesity?
CONCLUSION: These recommendations should optimize the use of NBs/BIs in ICU patients.
参考来源
- Dequin PF, Aubron C, Faure H, et al. The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference. Ann Intensive Care. 2023. PMID: 37400647. doi:10.1186/s13613-023-01155-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。